Abstract
Background: Fat and iron deposition confound measurements of R2* and proton density fat fraction (PDFF), respectively, yet their combined impact on reproducibility is poorly understood.Purpose: To evaluate the multi‐center, multi‐vendor reproducibility of PDFF and R2* quantification using a PDFF‐R2* phantom.Study Type: Prospective multi‐center, phantom study.Phantom: Commercial PDFF‐R2* phantom with simultaneously controlled combination of PDFF (0%–30%) and R2* (50–600 s−1) values.Field Strength/Sequence: 1.5‐T and 3‐T, three‐dimensional (3D) multi‐echo, spoiled‐gradient‐echo sequences, in four different centers, each with a different vendor.Assessment: Two acquisition protocols were used, optimized for moderate R2* (Protocol 1) and high R2* (Protocol 2), respectively. The phantom was imaged multiple times at one of the centers to assess its stability.Statistical Tests: Intraclass correlation coefficient (ICC), linear regression analysis, reproducibility coefficient (RDC) and repeatability coefficient (RC).Results: Excellent agreement was observed for PDFF measurements between centers, vendors, field strengths, and protocols (ICC = 0.97). Stratified by protocol, excellent agreement was observed, with ICC = 0.96 (RDC = 6.2%) for Protocol 1 and ICC = 0.99 (RDC = 3.8%) for Protocol 2. Increased variability in PDFF measurements was observed with increasing PDFF and especially with higher R2*. Excellent agreement was observed for R2* between centers, vendors, field strengths, and protocols (ICC = 0.99). Stratified by protocol, strong agreement was observed, with ICC = 0.988 (RDC = 66.7 s−1) for Protocol 1 and ICC = 0.99 (RDC = 57.7 s−1) for Protocol 2. Higher variability in R2* measurements was observed in vials with higher PDFF or R2*. Stability tests demonstrated an ICC = 1.0 for PDFF and R2*, and RC of 0.4% for PDFF and 12 s−1 for R2*.Data Conclusion: Excellent PDFF and R2* reproducibility was observed across centers, vendors, field strengths, and acquisition protocols. Reproducibility decreased slightly with increasing PDFF and R2*, especially for PDFF measurements in vials with high R2*.Evidence Level: N/A.Technical Efficacy: Stage 1.
Funding Information
  • National Institute of Health Sciences (R01 EB031886, R01CA283663)
  • Small Business Innovation Research (R44EB025729)
  • Cancer Prevention and Research Institute of Texas (RP190049)

This publication has 30 references indexed in Scilit: